12 Month Price Forecast For CRDF
Distance to CRDF Price Forecasts
CRDF Price Momentum
🤔 Considering Cardiff Oncology (CRDF)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 5:13 AM UTC
CRDF Analyst Ratings & Price Targets
Based on our analysis of 5 Wall Street analysts, CRDF has a consensus that is bullish. The median price target is $10.00, with forecasts ranging from $10.00 to $13.00. Currently, there are 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With CRDF currently trading at $3.54, the median price forecast suggests a 182.5% upside. The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 267.2% upside, while Joseph Catanzaro at Piper Sandler provides the most conservative target, suggesting a 182.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRDF Analyst Consensus
CRDF Price Target Range
Latest CRDF Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRDF.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 13, 2024 | Piper Sandler | Joseph Catanzaro | Overweight | Maintains | $10.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $13.00 |
| Sep 6, 2024 | Craig-Hallum | Albert Lowe | Buy | Initiates | $8.00 |
| May 6, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $14.00 |
| Mar 6, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $14.00 |
| Mar 1, 2024 | Piper Sandler | Joseph Catanzaro | Overweight | Maintains | $7.00 |
| Aug 11, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $12.00 |
| Aug 8, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $13.00 |
| May 9, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $14.00 |
| Mar 29, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $15.00 |
| Mar 7, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $15.00 |
| Sep 16, 2022 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $14.00 |
| Sep 13, 2022 | Piper Sandler | Joseph Catanzaro | Overweight | Maintains | $5.00 |
| Aug 29, 2022 | Baird | Joel Beatty | Outperform | Maintains | $6.00 |
| May 9, 2022 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $22.00 |
| Feb 28, 2022 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $25.00 |
| Dec 8, 2021 | Baird | Outperform | Initiates | $0.00 | |
| Aug 10, 2021 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $26.00 |
| May 10, 2021 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $25.00 |
| Oct 22, 2020 | HC Wainwright & Co. | Buy | Initiates | $0.00 |
Stocks Similar to Cardiff Oncology, Inc.
The following stocks are similar to Cardiff Oncology based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cardiff Oncology, Inc. (CRDF) Financial Data
Cardiff Oncology, Inc. has a market capitalization of $234.17M with a P/E ratio of -3.8x. The company generates $688,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +17.0% quarter-over-quarter, while maintaining an operating margin of -7,637.0% and return on equity of -67.6%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Cardiff Oncology, Inc. (CRDF) Company Overview
About Cardiff Oncology, Inc.
Develops therapies for various cancers.
Cardiff Oncology, Inc. operates as a clinical-stage biotechnology company focusing on developing innovative cancer treatments. The company generates revenue primarily through collaborations and partnerships with pharmaceutical manufacturers, leveraging its lead drug candidate, onvansertib, and other therapies in its pipeline.
The company, originally known as Trovagene, Inc., rebranded in May 2012 and has been active since its incorporation in 1999. Based in San Diego, California, it is pursuing treatments for multiple types of cancers, including those that are difficult to treat, such as KRAS/NRAS-mutated cancers.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
31
CEO
Dr. Mark Erlander Ph.D.
Country
United States
IPO Year
2019
Website
www.cardiffoncology.comCardiff Oncology, Inc. (CRDF) Latest News & Analysis
Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning
1 month agoCardiff Oncology's phase 2 trial of onvansertib in mCRC shows promising results and improved response rates. An equity raise enhances cash runway, supporting ongoing development and reducing financial risk.
Cardiff Oncology's promising trial results and extended cash runway reduce financial risk and enhance potential for future growth, signaling a positive outlook for investors.
The 'Undercovered' Dozen series features Ubiquiti Inc. for operational improvements, Ready Capital for liquidity risks, and TORM plc amid energy volatility. Esperion and Cardiff Oncology show strong buy potential, while Advantest may require caution due to high valuation.
Emerging stocks like Ubiquiti and Esperion offer potential upside, while others like Ready Capital and Advantest highlight risks. Insights from the 'Undercovered' series can guide strategic investments.
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial
1 month agoPhase 2 trial results show onvansertib combined with standard care achieved a 64% objective response rate (ORR) in RAS-mut mCRC patients, compared to 33% in the control group.
The higher overall response rate (ORR) for onvansertib suggests strong efficacy, potentially increasing its market value and attractiveness to investors in biotech and pharmaceutical sectors.
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering
1 month agoCardiff Oncology, Inc. priced an underwritten offering of 15.4 million shares at $2.60 each, aiming to raise capital with participation from new and existing investors.
Cardiff Oncology's stock offering at $2.60 reflects capital-raising efforts, potentially diluting existing shares but attracting new institutional investors, signaling confidence in its cancer therapies.
Cardiff Oncology stock rises following positive initial phase II study data showing onvansertib's superior efficacy compared to standard chemotherapy in colorectal cancer patients.
Cardiff Oncology's stock surge indicates strong potential for onvansertib, suggesting increased investor confidence and possible future revenue from enhanced treatment options in colorectal cancer.
Cardiff Oncology's Phase 2 trial for Onvansertib in metastatic colorectal cancer reported a 57% overall response rate, outperforming the 33% control. The company secured $40M in funding and plans FDA discussions for accelerated approval.
Cardiff Oncology's promising trial results and potential FDA discussions may lead to accelerated drug approval, boosting investor confidence. The strong financial backing enhances operational stability.
Frequently Asked Questions About CRDF Stock
What is Cardiff Oncology, Inc.'s (CRDF) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Cardiff Oncology, Inc. (CRDF) has a median price target of $10.00. The highest price target is $13.00 and the lowest is $10.00.
Is CRDF stock a good investment in 2025?
According to current analyst ratings, CRDF has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.54. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CRDF stock?
Wall Street analysts predict CRDF stock could reach $10.00 in the next 12 months. This represents a 182.5% increase from the current price of $3.54. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cardiff Oncology, Inc.'s business model?
Cardiff Oncology, Inc. operates as a clinical-stage biotechnology company focusing on developing innovative cancer treatments. The company generates revenue primarily through collaborations and partnerships with pharmaceutical manufacturers, leveraging its lead drug candidate, onvansertib, and other therapies in its pipeline.
What is the highest forecasted price for CRDF Cardiff Oncology, Inc.?
The highest price target for CRDF is $13.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 267.2% increase from the current price of $3.54.
What is the lowest forecasted price for CRDF Cardiff Oncology, Inc.?
The lowest price target for CRDF is $10.00 from Joseph Catanzaro at Piper Sandler, which represents a 182.5% increase from the current price of $3.54.
What is the overall CRDF consensus from analysts for Cardiff Oncology, Inc.?
The overall analyst consensus for CRDF is bullish. Out of 5 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are CRDF stock price projections?
Stock price projections, including those for Cardiff Oncology, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
